Vaccine Research

Jens Meiler, Distinguished Research Professor of Chemistry, was named the principal investigator for the project, in cooperation with 14 investigators across eight institutions. The team will work together to use advanced technology, including computational modeling, AI-driven predictions and structural biology, to develop a groundbreaking vaccine against all alphaviruses that offers long-lasting protection. Read More

VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections. Read More

The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center. Read More

It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks. Read More

There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years. Read More

In late 2013 the Caribbean had its first case of the mosquito-borne chikungunya virus. Today there have been almost 1.2 million cases in 44 countries or territories, including 177 cases in 31 U.S. States. Read More